Antibodies against the rgm a protein and uses thereof
AssigneesAbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
InventorsBernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
Life of this patent
Estimating the term…
Abstract
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
Claims6
-91. (canceled)
An isolated monoclonal anti-Repulsive Guidance Molecule A (RGMA) antibody comprising a heavy chain variable region comprising a complementarity determining region(CDR)1 with the amino acid sequence set forth in SEQ ID NO:57, a CDR2 with the amino acid sequence set forth in SEQ ID NO:58, a CDR3 with the amino acid sequence set forth in SEQ ID NO:59;
- and a light chain variable region comprising a CDR1 with the amino acid sequence set forth in SEQ ID NO:60, a CDR2 with the amino acid sequence set forth in SEQ ID NO:61, a CDR3 with the amino acid sequence set forth in SEQ ID NO:62
Dependencies are inferred from the claim text.